Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Case report

Case report: 8 years after liver transplantation: de novo hepatocellular carcinoma 8 months after HCV clearance through IFN-free antiviral therapy

Authors: Giuliano Ramadori, Patrizia Bosio, Federico Moriconi, Ihtzaz A. Malik

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

After orthotopic liver transplantation (OLT) for hepatocellular carcinoma (HCC), recurrent HCC mostly develops within 2 years. All cases of de novo HCC described so far occurred later than 2 years after OLT. Prevention of post-transplantation HCC has usually been tried to achieve by curing or controlling recurrent liver disease. This has been rationale for treatment with interferon (IFN)/ribavirin of HCV-recurrence in patients after OLT, transplanted for advanced HCV-induced liver disease and/or HCC. The availability of new and more efficient drugs has improved chances also for previously difficult-to-treat HCV-positive patients.

Case presentation

A 75 year-old male patient who had undergone OLT for decompensated HCV-cirrhosis in 2009, and bilio-digestive surgery in 2011 under tracrolimus (0.5 mg/day) and prednisone (5 mg/day) immunosuppressive therapy, started to receive antiviral treatment for recurrent HCV-infection of graft with 200 mg/day ribavirin in combination with ledipasvir and sofosbuvir by the end of October 2015. Because of multiple side effects (anemia, asthenia, infections, and reduction of kidney functions - palliated by treatment with erythropoietin), treatment was stopped after 16 weeks. At the third control, a minimal increase in alpha-fetoprotein (AFP) serum level to 10 μg/L was measured 8 months after therapy, whereas both liver sonography and serum transaminases were normal. The patient’s general condition; however, remained poor, and a magnetic resonance imaging (MRI) of abdomen was performed 2 months later. A nodule of 3 cm in diameter with a pseudocapsule was found centrally in the liver. The patient had to be hospitalized for recurrent infections of the lung, overt ascites and peritonitis. Rapid tumor growth (10 cm) was detected during last stay in hospital (April 2017), concomitant with a rise of AFP-serum levels to 91 μg/L. The family decided to take the patient home, and best supportive care was provided by a general practitioner, local nurses and the patient’s dedicated wife until his death.

Conclusion

Before treating OLT patients with HCV graft reinfection one should not only consider possible advantages of newly effective antiviral-therapies, but also life expectancy and possible side effects (difficult to manage at an outpatient service basis), including severe disadvantages such as the development of HCC.
Literature
1.
Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333–42.CrossRefPubMed
2.
3.
Amanzada A, Schneider S, Moriconi F, Lindhorst A, Suermann T, van Thiel DH, et al. Early anemia and rapid virological response improve the predictive efficiency of IL28B-genotype for treatment outcome to antiviral combination therapy in patients infected with chronic HCV genotype 1. J Med Virol. 2012;84:1208–16.CrossRefPubMed
4.
Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013;158:329–37.CrossRefPubMed
5.
6.
Goutté N, Sogni P, Bendersky N, Barbare JC, Falissard B, Farges O. Geographical variations in incidence, management and survival of hepatocellular carcinoma in a western country. J Hepatol. 2017;66:537–44.CrossRefPubMed
7.
Innes H, McDonald S, Hayes P, Dillon JF, Allen S, Goldberg D, et al. Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population. J Hepatol. 2017;66:19–27.CrossRefPubMed
8.
Roche B, Samuel D. Antiviral therapy in HCV-infected cirrhotics awaiting liver transplantation: a costly strategy for mixed virological results. J Hepatol. 2009;50:652–4.CrossRefPubMed
9.
Féray C, Caccamo L, Alexander GJ, Ducot B, Gugenheim J, Casanovas T, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European concerted action on viral hepatitis (EUROHEP) group. Gastroenterology. 1999;117:619–25.CrossRefPubMed
10.
Forns X, García-Retortillo M, Serrano T, Feliu A, Suarez F, de la Mata M, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol. 2003;39:389–96.CrossRefPubMed
11.
Everson GT, Trotter J, Forman L, Kugelmas M, Halprin A, Fey B, et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology. 2005;42:255–62.CrossRefPubMed
12.
Crespo G, Mariño Z, Navasa M, Forns X. Viral hepatitis in liver transplantation. Gastroenterology. 2012;142:1373–1383.e1.CrossRefPubMed
13.
Everson GT, Terrault NA, Lok AS, Rodrigo DR, Brown RS, Saab S, et al. A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology. 2013;57:1752–62.CrossRefPubMedPubMedCentral
14.
Aleman S, Rahbin N, Weiland O, Davidsdottir L, Hedenstierna M, Rose N, et al. A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin Infect Dis. 2013;57:230–6.CrossRefPubMed
15.
Jiménez-Pérez M, González-Grande R, Rando-Muñoz FJ. Management of recurrent hepatitis C virus after liver transplantation. World J Gastroenterol. 2014;20:16409–17.CrossRefPubMedPubMedCentral
16.
Berenguer M, Schuppan D. Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment. J Hepatol. 2013;58:1028–41.CrossRefPubMed
17.
Dumitra S, Alabbad SI, Barkun JS, Dumitra TC, Coutsinos D, Metrakos PP, et al. Hepatitis C infection and hepatocellular carcinoma in liver transplantation: a 20-year experience. HPB. 2013;15:724–31.CrossRefPubMedPubMedCentral
18.
Sanai FM, Mousa D, Al-Mdani A, Al-Shoail G, Al-Ashgar H, Al Meshari K, et al. Safety and efficacy of peginterferon-α2a plus ribavirin treatment in renal transplant recipients with chronic hepatitis C. J Hepatol. 2013;58:1096–103.CrossRefPubMed
19.
Fagiuoli S, Ravasio R, Lucà MG, Baldan A, Pecere S, Vitale A, et al. Management of hepatitis C infection before and after liver transplantation. World J Gastroenterol. 2015;21:4447–56.CrossRefPubMedPubMedCentral
20.
Coilly A, Roche B, Duclos-Vallée J-C, Samuel D. Optimum timing of treatment for hepatitis C infection relative to liver transplantation. Lancet Gastroenterol Hepatol. 2016;1:165–72.CrossRefPubMed
21.
Singal AK, Freeman DH, Anand BS. Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Aliment Pharmacol Ther. 2010;32:851–8.CrossRefPubMed
22.
Xu J, Li J, Chen J, Liu Z-J. Effect of adjuvant interferon therapy on hepatitis b/c virus-related hepatocellular carcinoma after curative therapy - meta-analysis. Adv Clin Exp Med Off Organ Wroclaw Med Univ. 2015;24:331–40.CrossRef
23.
Hsu Y-C, Ho HJ, Wu M-S, Lin J-T, Wu C-Y. Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma. Hepatology. 2013;58:150–7.CrossRefPubMed
24.
Zhang D-W, Song T-Q, Zhang T, Wu Q, Kong D-L, Li Q, et al. Adjuvant interferon for early or late recurrence of hepatocellular carcinoma and mortality from hepatocellular carcinoma following curative treatment: a meta-analysis with comparison of different types of hepatitis. Mol Clin Oncol. 2014;2:1125–34.CrossRefPubMedPubMedCentral
25.
Trevisani F, Garuti F, Cucchetti A, Lenzi B, Bernardi M. De novo hepatocellular carcinoma of liver allograft: a neglected issue. Cancer Lett. 2015;357:47–54.CrossRefPubMed
26.
Reig M, Mariño Z, Perelló C, Iñarrairaegui M, Ribeiro A, Lens S, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 2016;65:719–26.CrossRefPubMed
27.
Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016;65:727–33.CrossRefPubMed
28.
Lencioni R, Cioni D, Crocetti L, Della Pina C, Bartolozzi C. Magnetic resonance imaging of liver tumors. J Hepatol. 2004;40:162–71.CrossRefPubMed
29.
Hézode C, Bronowicki J-P. Ideal oral combinations to eradicate HCV: the role of ribavirin. J Hepatol. 2016;64:215–25.CrossRefPubMed
30.
Wirth TC, Manns MP. The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma. Ann Oncol. 2016;27:1467–74.CrossRefPubMed
31.
Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016;63:1493–505.CrossRefPubMedPubMedCentral
32.
Nahon P, Bourcier V, Layese R, Audureau E, Cagnot C, Marcellin P, et al. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology. 2017;152:142–156.e2.CrossRefPubMed
33.
Nault J-C, Colombo M. Hepatocellular carcinoma and direct acting antiviral treatments: controversy after the revolution. J Hepatol. 2016;65:663–5.CrossRefPubMed
34.
Toyoda H, Kumada T, Tada T. Changes in patient backgrounds may increase the incidence of HCC after SVR in the era of IFN-free therapy for HCV. Hepatology. 2016;64:1818–9.CrossRefPubMed
35.
Ravi S, Axley P, Jones D, Kodali S, Simpson H, McGuire BM, et al. Unusually high rates of hepatocellular carcinoma after treatment with direct-acting antiviral therapy for hepatitis C related cirrhosis. Gastroenterology. 2017;152:911–2.CrossRefPubMed
36.
Tsai P-C, Huang C-F, Yu M-L. Unexpected early tumor recurrence in patients with hepatitis C virus-related hepatocellular carcinoma undergoing interferon-free therapy: issue of the interval between HCC treatment and antiviral therapy. J Hepatol. 2017;66:464.CrossRefPubMed
37.
Kolly P, Dufour J-F. A strong message is needed to address the issue of HCC recurrence after DAA therapy. J Hepatol. 2016;65:1268–9.CrossRefPubMed
38.
Carrat F, Nahon P, Duclos-Vallée JC, Pageaux GP, Fontaine H, Pol S, et al. Reply to “a strong message is needed to address the issue of HCC recurrence after DAA therapy”. J Hepatol. 2016;65:1269–70.CrossRefPubMed
39.
Zavaglia C, Okolicsanyi S, Cesarini L, Mazzarelli C, Pontecorvi V, Ciaccio A, et al. Is the risk of neoplastic recurrence increased after prescribing direct-acting antivirals for HCV patients whose HCC was previously cured? J Hepatol. 2017;66:236–7.CrossRefPubMed
40.
Zeng Q-L, Li Z-Q, Liang H-X, Xu G-H, Li C-X, Zhang D-W, et al. Unexpected high incidence of hepatocellular carcinoma in patients with hepatitis C in the era of DAAs: too alarming? J Hepatol. 2016;65:1068–9.CrossRefPubMed
41.
Torres HA, Vauthey J-N, Economides MP, Mahale P, Kaseb A. Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals: first, do no harm by withdrawing treatment. J Hepatol. 2016;65:862–4.CrossRefPubMed
42.
Reig M, Torres F, Mariño Z, Forns X, Bruix J. Reply to “direct antiviral agents and risk for hepatocellular carcinoma (HCC) early recurrence: much ado about nothing”. J Hepatol. 2016;65:864–5.CrossRefPubMed
43.
Yang JD, Aqel BA, Pungpapong S, Gores GJ, Roberts LR, Leise MD. Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma. J Hepatol. 2016;65:859–60.CrossRefPubMed
44.
Morita K, Taketomi A, Soejima Y, Ikegami T, Fukuhara T, Iguchi T, et al. De novo hepatocellular carcinoma in a liver graft with sustained hepatitis C virus clearance after living donor liver transplantation. Liver Transpl. 2009;15:1412–6.CrossRefPubMed
Metadata
Title
Case report: 8 years after liver transplantation: de novo hepatocellular carcinoma 8 months after HCV clearance through IFN-free antiviral therapy
Authors
Giuliano Ramadori
Patrizia Bosio
Federico Moriconi
Ihtzaz A. Malik
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-4175-2

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue

Research article

Breast cancer primary tumor ER expression pattern predicts its expression concordance in matched synchronous lymph node metastases

Technical advance

Simultaneous detection of lung fusions using a multiplex RT-PCR next generation sequencing-based approach: a multi-institutional research study

Case report

Coexistence of gastric gastrointestinal stromal tumor, intro-abdominal and retroperitoneal liposarcomas –a case report

Research article

Estrogen receptor β is associated with expression of cancer associated genes and survival in ovarian cancer

Research article

KIBRA; a novel biomarker predicting recurrence free survival of breast cancer patients receiving adjuvant therapy

Research article

Untargeted lipidomic features associated with colorectal cancer in a prospective cohort
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits